{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:18:14Z","timestamp":1793830694568,"version":"4.6.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1093\/rheumatology\/keg072","type":"journal-article","created":{"date-parts":[[2003,2,21]],"date-time":"2003-02-21T00:25:23Z","timestamp":1045787123000},"page":"244-257","source":"Crossref","is-referenced-by-count":894,"title":["A simplified disease activity index for rheumatoid arthritis for use in clinical practice"],"prefix":"10.1093","volume":"42","author":[{"given":"J. S.","family":"Smolen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. C.","family":"Breedveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. H.","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Kalden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Eberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L.","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,2]]},"reference":[{"key":"key\n\t\t\t\t20170703112054_R1","doi-asserted-by":"crossref","unstructured":"Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum1993;36:729\u201340.","DOI":"10.1002\/art.1780360601"},{"key":"key\n\t\t\t\t20170703112054_R2","doi-asserted-by":"crossref","unstructured":"van Gestel AM, van Riel PLCM. Evaluation of early rheumatoid arthritis disease activity and outcome. Bailli\u00e8re's Clin Rheumatol1997;11:49\u201363.","DOI":"10.1016\/S0950-3579(97)80032-5"},{"key":"key\n\t\t\t\t20170703112054_R3","doi-asserted-by":"crossref","unstructured":"Boers M, Tugwell P, Brooks PM. Progress towards optimal trial end\u2010points in rheumatoid arthritis. BioDrugs1997;7:40\u201350.","DOI":"10.2165\/00063030-199707010-00006"},{"key":"key\n\t\t\t\t20170703112054_R4","unstructured":"Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol1993;20:561\u20135."},{"key":"key\n\t\t\t\t20170703112054_R5","doi-asserted-by":"crossref","unstructured":"van Riel PLCM, van Gestel AM, van de Putte LBA. Development and validation of response criteria in rheumatoid arthritis: steps towards an international consensus on prognostic markers. Br J Rheumatol1996;35(Suppl. 2):4\u20137.","DOI":"10.1093\/rheumatology\/35.suppl_2.4"},{"key":"key\n\t\t\t\t20170703112054_R6","unstructured":"Boers M, Tugwell P. OMERACT conference questionnaire results. OMERACT Committee. J Rheumatol1993;20:552\u20134."},{"key":"key\n\t\t\t\t20170703112054_R7","doi-asserted-by":"crossref","unstructured":"Paulus HE, Egger JR, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease\u2010modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum1990;33:477\u201384.","DOI":"10.1002\/art.1780330403"},{"key":"key\n\t\t\t\t20170703112054_R8","unstructured":"Tugwell P, Boers M, Baker P, Wells G, Snider J. Endpoints in rheumatoid arthritis. J Rheumatol1994;21:2\u20138."},{"key":"key\n\t\t\t\t20170703112054_R9","unstructured":"Boers M, Tugwell P, Felson DT et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl1994;41:86\u20139."},{"key":"key\n\t\t\t\t20170703112054_R10","doi-asserted-by":"crossref","unstructured":"van der Heijde DMFM, Van't Hof MA, van Riel PLCM et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis1990;49:916\u201320.","DOI":"10.1136\/ard.49.11.916"},{"key":"key\n\t\t\t\t20170703112054_R11","doi-asserted-by":"crossref","unstructured":"van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum1998;41:1845\u201350.","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"key\n\t\t\t\t20170703112054_R12","doi-asserted-by":"crossref","unstructured":"Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum1995;38:727\u201335.","DOI":"10.1002\/art.1780380602"},{"key":"key\n\t\t\t\t20170703112054_R13","doi-asserted-by":"crossref","unstructured":"van Gestel AM, Prevoo MLL, Van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum1996;39:34\u201340.","DOI":"10.1002\/art.1780390105"},{"key":"key\n\t\t\t\t20170703112054_R14","unstructured":"van Gestel AM, Anderson JJ, van Riel PLCM et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol1999;26:705\u201311."},{"key":"key\n\t\t\t\t20170703112054_R15","unstructured":"van der Heijde DMFM, Van't Hof MA, van Riel PLCM, van de Putte LBA. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. J Rheumatol1993;20:538\u201341."},{"key":"key\n\t\t\t\t20170703112054_R16","doi-asserted-by":"crossref","unstructured":"Eberl G, Studnicka\u2010Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology2000;39:148\u201355.","DOI":"10.1093\/rheumatology\/39.2.148"},{"key":"key\n\t\t\t\t20170703112054_R17","doi-asserted-by":"crossref","unstructured":"Smolen JS, Kalden JR, Scott DL et al. European Leflunomide Study Group: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double\u2010blind, randomised, multicentre trial. Lancet1999;353:259\u201366.","DOI":"10.1016\/S0140-6736(98)09403-3"},{"key":"key\n\t\t\t\t20170703112054_R18","doi-asserted-by":"crossref","unstructured":"Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate. Arch Intern Med1999;159:2542\u201350.","DOI":"10.1001\/archinte.159.21.2542"},{"key":"key\n\t\t\t\t20170703112054_R19","doi-asserted-by":"crossref","unstructured":"Emery P, Breedveld FC, Lemmel EM et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology2000;39:655\u201365.","DOI":"10.1093\/rheumatology\/39.6.655"},{"key":"key\n\t\t\t\t20170703112054_R20","doi-asserted-by":"crossref","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988;31:315\u201324.","DOI":"10.1002\/art.1780310302"},{"key":"key\n\t\t\t\t20170703112054_R21","doi-asserted-by":"crossref","unstructured":"Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc1949;140:659\u201362.","DOI":"10.1001\/jama.1949.02900430001001"},{"key":"key\n\t\t\t\t20170703112054_R22","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol1993;20:557\u201360."},{"key":"key\n\t\t\t\t20170703112054_R23","doi-asserted-by":"crossref","unstructured":"Schiff MH, Strand V, Oed C, Loew\u2010Friedrich I. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today2000;36:383\u201394.","DOI":"10.1358\/dot.2000.36.6.584259"},{"key":"key\n\t\t\t\t20170703112054_R24","doi-asserted-by":"crossref","unstructured":"Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty\u2010eight\u2010joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum1989;32:531\u20137.","DOI":"10.1002\/anr.1780320504"},{"key":"key\n\t\t\t\t20170703112054_R25","doi-asserted-by":"crossref","unstructured":"Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty\u2010eight\u2010joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum1995;38:38\u201343.","DOI":"10.1002\/art.1780380106"},{"key":"key\n\t\t\t\t20170703112054_R26","unstructured":"Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol1991;18:1298\u2013306."},{"key":"key\n\t\t\t\t20170703112054_R27","doi-asserted-by":"crossref","unstructured":"van der Heide A, Jacobs JW, Dinant HJ, Bijlsma JW. The impact of endpoint measures in rheumatoid arthritis clinical trials. Semin Arthritis Rheum1992;21:287\u201394.","DOI":"10.1016\/0049-0172(92)90022-6"},{"key":"key\n\t\t\t\t20170703112054_R28","doi-asserted-by":"crossref","unstructured":"Anderson JJ, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum1989;32:1093\u20139.","DOI":"10.1002\/anr.1780320907"},{"key":"key\n\t\t\t\t20170703112054_R29","doi-asserted-by":"crossref","unstructured":"Bombardier C, Raboud J, Auranofin Cooperating Group. A comparison of health\u2010related quality\u2010of\u2010life measures for rheumatoid arthritis research. Control Clin Trials1991;12(Suppl.):243\u201356S.","DOI":"10.1016\/S0197-2456(05)80028-5"},{"key":"key\n\t\t\t\t20170703112054_R30","unstructured":"Anderson JJ, Chernoff MC. Sensitivity to change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol1993;20:535\u20137."},{"key":"key\n\t\t\t\t20170703112054_R31","doi-asserted-by":"crossref","unstructured":"Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time\u2010integrated C\u2010reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum2000;43:1473\u20137.","DOI":"10.1002\/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N"},{"key":"key\n\t\t\t\t20170703112054_R32","doi-asserted-by":"crossref","unstructured":"Aman S, Paimela L, Leirisalo\u2010Repo M et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3\u2010year follow\u2010up study. Rheumatology2000;39:1009\u201313.","DOI":"10.1093\/rheumatology\/39.9.1009"},{"key":"key\n\t\t\t\t20170703112054_R33","unstructured":"Listing J, Rau R, Muller B et al. HLA\u2010DRB1 genes, rheumatoid factor, and elevated C\u2010reactive protein: independent risk factors of radiographic progression in early rheumatoid arthritis. Berlin Collaborating Rheumatological Study Group. J Rheumatol2000;27:2100\u20139."},{"key":"key\n\t\t\t\t20170703112054_R34","doi-asserted-by":"crossref","unstructured":"Drossaers\u2010Bakker KW, De Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW. Long\u2010term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time. Arthritis Rheum1999;42:1854\u201360.","DOI":"10.1002\/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F"},{"key":"key\n\t\t\t\t20170703112054_R35","unstructured":"Wolfe F, Hawley DJ. The long\u2010term outcomes of rheumatoid arthritis: work disability: A prospective 18 year study of 823 patients. J Rheumatol1998;25:2108\u201317."},{"key":"key\n\t\t\t\t20170703112054_R36","doi-asserted-by":"crossref","unstructured":"Scott DL, Pugner K, Kaarela K et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology2000;39:122\u201332.","DOI":"10.1093\/rheumatology\/39.2.122"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/42\/2\/244\/18095765\/420244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T17:47:06Z","timestamp":1584467226000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-lookup\/doi\/10.1093\/rheumatology\/keg072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,2]]},"published-print":{"date-parts":[[2003,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keg072","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}